Friends,

I recently sat down with Dr. Colleen Cutcliffe, CEO of Pendulum Therapeutics, for a discussion about probiotics, metabolism, and a potential natural alternative to GLP-1 drugs like Ozempic. Here's why I'm excited to share this with you...

The Backstory

A month ago, I ran into a friend who had slimmed down and was looking fit. These days, I’ve had a good dozen or so friends lose weight with GLP-1 drugs, so I was surprised when she told me it wasn’t Ozempic but Pendulum's new GLP-1 probiotic. Her chocolate cravings (her usual downfall) had changed entirely. Instead of demolishing a whole bar, she could have one bite and walk away satisfied.

I've known Pendulum for years (we invested at True), and I've personally used their glucose control product with great success. However, I had lost touch with Colleen and didn’t realize they had a new GLP-1 product — so I asked her to come on the podcast and discuss it.

Note: Peter Attia did a much longer and more thorough deep-dive with Colleen, found here

What Makes This Different?

In my interview with Colleen, she explained how their probiotic actually helps your body produce its own GLP-1 hormone naturally. The science is fascinating – they've identified specific strains of bacteria that, when delivered to your gut's distal colon, help stimulate natural GLP-1 production. No shots, no prescription.

The results are pretty impressive; 91% of users reported reduced food cravings after six weeks*, and the higher the initial cravings, the more significant the improvement.

Why This Matters

Over the last year+, I've watched friends scramble to find GLP-1 prescriptions, hitting up sketchy compounding pharmacies, or paying astronomical prices when their insurance won't cover them. It's wild out there.But obesity isn't just about weight – it's tied to heart disease, diabetes, cancer, and even cognitive decline (some scientists are calling Alzheimer's "Type 3 diabetes"). We need better solutions that are both accessible and backed by science.

Join Our Mini-Trial

Sadly, the trial is now closed — thanks to all who participated!

What's Next?

We'll be collecting data throughout the trial and sharing the results with participants. Stay tuned for updates on how the community is progressing.

Exciting stuff ahead! As always, I'd love to hear your thoughts and experiences if you decide to participate.

Until next time, be well,

*based on a consumer survey of 274 people

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.kevinrose.com/subscribe